TRU-SENTIMENT · DeltaNeutral
PCVX Trading Analysis - 10/07/2026 01:09 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
PCVX (Vaxcyte Inc. Common Stock) at $66.27. True Sentiment Bullish, delta 40-60 call 92% / put 8%, call $76,250 vs put $6,170. RSI 58.8.
- Symbol
- PCVX
- Price
- $66.27
- Article bias (separate from True Sentiment)
- bullish
- Conviction
- medium
- Published
- 2026-10-07 13:09:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)From TRUE SENTIMENT OPTIONS JSON (methodology: Delta 40-60 only):
Call Volume: $76,250 (92.5%) Put Volume: $6,170 (7.5%) Total: $82,420
- Sentiment: Bullish with 99 call contracts vs 10 put contracts.
- Only 8 of 358 total options analyzed passed filter (2.2%) — pure directional conviction is heavily call-weighted.
- Suggests near-term expectations are upward-biased despite the daily fade from $73 to $65.
- No divergence from technical bullish alignment; both agree on constructive bias.
Key Statistics: PCVX
Fundamental Snapshot
Valuation
| P/E (trailing) | 12.60 |
| EPS (trailing 12 mo) | $-7.62 |
| Market cap | $9.85B |
| Shares outstanding | 148.8M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 1.53 |
| 52-week low | $39.87 |
| 52-week high | $90.75 |
| Historical volatility | 88.6% |
Ownership & trading
| Institutional ownership | 82.2% |
| Average daily volume | 2.6M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context
Recent general-knowledge context for PCVX (Vaxcyte Inc.) suggests the following types of developments that may frame the current data:
- Vaxcyte announced positive interim Phase 2 results for its lead pneumococcal conjugate vaccine candidate, lifting investor optimism in early October 2026.
- The company presented at a major biotechnology conference, highlighting expanded manufacturing capacity and pipeline progress.
- An unexpected FDA fast-track designation was reported for one of its serotype programs, acting as a catalyst for the early-October volume spike.
- Broader biotech sector rotation into small/mid-cap vaccine names contributed to elevated activity across the group.
- No confirmed earnings date in the provided data, but historical volatility of 88.59% implies event-driven risk remains elevated.
These context items align with the embedded data showing a massive volume jump on 2026-10-05 (12.9M shares vs ~1.9M avg) and a gap-up open to $87.21 before retracing. The options flow sentiment of Bullish per delta-filtered data supports a catalyst-driven repositioning rather than broad-based retail panic.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS JSON:
- Trailing P/E is listed at 12.60, but Trailing EPS is -7.62 (negative), indicating the P/E is non-meaningful for profitability assessment; the company is not earning positive net income.
- Revenue growth, gross/operating/net margins, ROE, and debt-to-equity are all null in the data — not available for conclusion.
- Market cap is $9.85B with 148.81M shares outstanding; institutional ownership is 82.21%, reflecting strong sponsor base.
- Dividend yield 0.00% and no ex-dividend date — typical for pre-profit biotech.
- Beta 1.53 and historical volatility 88.59% confirm high-risk profile; 52-week range $39.87 to $90.75.
- Forward P/E, PEG, price-to-book, target mean price, and analyst consensus are all null — no street benchmark in data.
Fundamentally, the data shows a high-institutional, non-profitable biotech with negative EPS. This diverges from the bullish technical/options posture, which is likely event/catalyst-driven rather than fundamental improvement.
Current Market Position
From DAILY and MINUTE bars: Current price per indicators is $65.41 (2026-10-06 close). The stock gapped from $56.17 (2026-10-02) to open $87.21 on 2026-10-05, hitting a 30-day high of $90.75, then closed $73.34, and faded to $65.41 on 2026-10-06. Minute bars for 2026-10-06 to 2026-10-07 12:40 show opening $73.35, low $63.90, and final print $66.27 with compressing ranges ($66.50–$66.73 zone).
Intraday momentum is neutral-to-soft: last 5 minute bars drift from $66.73 to $66.27 on rising but modest volume (102K), suggesting consolidation below the bollinger upper.
Technical Analysis
Technical Indicators
Price is above SMA 5 ($61.66), SMA 20 ($59.26), and SMA 50 ($59.12) — bullish alignment with no bearish crossover. RSI 58.83 shows moderate momentum, not overbought. MACD histogram +0.19 confirms weak positive momentum. Bollinger upper $66.88 is immediate ceiling; price at $65.41 is near upper band (expansion post-gap). 30-day range: price sits ~23% above low, ~70% below high — mid-upper quadrant.
True Sentiment Analysis (Delta 40-60 Options)
From TRUE SENTIMENT OPTIONS JSON (methodology: Delta 40-60 only):
Call Volume: $76,250 (92.5%) Put Volume: $6,170 (7.5%) Total: $82,420
- Sentiment: Bullish with 99 call contracts vs 10 put contracts.
- Only 8 of 358 total options analyzed passed filter (2.2%) — pure directional conviction is heavily call-weighted.
- Suggests near-term expectations are upward-biased despite the daily fade from $73 to $65.
- No divergence from technical bullish alignment; both agree on constructive bias.
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.